Company Tekmira Pharmaceuticals Corporation Toronto S.E.
Equities
TKM
CA87911B2093
Pharmaceuticals
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 39 | 100.0 % | 18 | 100.0 % | -53.51% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 39 | 100.0 % | 18 | 100.0 % | -53.51% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 30/06/14 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 10/06/18 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | 53 | 31/03/17 |
Michael Sofia
CTO | Chief Tech/Sci/R&D Officer | 66 | 28/02/15 |
John Naftzger
CMP | Compliance Officer | 57 | 09/07/23 |
Investor Relations Contact | - | 20/09/21 | |
Shannon Briscoe
HRO | Human Resources Officer | - | 30/06/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 30/11/14 | |
James Meyers
BRD | Director/Board Member | 59 | 22/10/18 |
Daniel Burgess
BRD | Director/Board Member | 62 | 22/03/17 |
Keith Manchester
BRD | Director/Board Member | 55 | 03/03/15 |
Frank Torti
CHM | Chairman | 45 | 25/11/18 |
Chief Executive Officer | 50 | 30/06/14 | |
Director/Board Member | 54 | 11/07/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 188,717,409 | 138,114,650 ( 73.19 %) | 0 | 73.19 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-3.89% | 88.14B | |
+1.45% | 40.51B | |
-14.79% | 31.67B | |
+51.20% | 24.62B | |
-15.07% | 15.65B | |
-13.95% | 12.07B | |
-7.87% | 11.97B | |
-39.40% | 11.61B | |
+5.62% | 8.81B |